—
C+
C+ The full Closelook — membership. Open the C+ overview

Organon & Co (OGN) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Organon & Co

OGN in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Organon makes and sells medicines and devices focused on women's health, including long-acting contraceptives such as Nexplanon and the NuvaRing vaginal ring, plus fertility treatments such as Follistim and Elonva. It also carries a wide range of older branded medicines inherited from its former parent, covering cholesterol, blood pressure, respiratory and skin conditions, alongside a group of biosimilar antibodies used in immunology and oncology. It was spun out as an independent company, is based in Jersey City and sells through wholesalers, retailers and hospitals across many countries.
Where it sits in the stack
Organon carries no seat in the AI build-out stack; it sits in the diary's healthcare universe as a diversified drug maker, not as a constraint on or a customer of any layer we track for the build-out.
Who it is priced against
Closelook has not set a peer group for this name; the comparison the market often draws is with Viatris, another company built from a big pharma's off-patent and legacy brands.
Why Closelook tracks it
Organon holds a seat in the Russell 1000 but carries no Closelook score yet, and the diary has not logged any quotes or editions on it so far.
What the diary watches
The diary watches whether growth in the women's health brands offsets the slow decline of the older branded medicines as they lose patent protection.

Organon & Co (OGN) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for OGN, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against OGN on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 0.58%, quarterly · last 0.0200 USD on 2026-08-14

Dividends and capital return

What OGN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.0799 USD per share · a 0.58% yield on the 2026-09-17 close 4 distributions, paid quarterly 2026-09-17
  • Change on the year −86.7% against the prior twelve months prior twelve months 0.60 USD per share
  • Last distribution 0.0200 USD per share as the price series records it, within days of the ex-date 2026-08-14
  • By calendar year 2023: 0.28 USD (partial) · 2024: 1.12 USD · 2025: 0.34 USD · 2026: 0.0600 USD to date first distribution recorded in the three-year window: 2023-11-10

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Organon & Co (OGN)?

Organon & Co trades as OGN on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is OGN in a Closelook index?

Not currently — Organon & Co is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does OGN trade against its moving averages?

Uptrend stack intact: Trades +0.4% vs the 50-day and +30.1% vs the 200-day average, 0.7% below the 52-week high and +141% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Organon & Co do?

Organon makes and sells medicines and devices focused on women's health, including long-acting contraceptives such as Nexplanon and the NuvaRing vaginal ring, plus fertility treatments such as Follistim and Elonva. It also carries a wide range of older branded medicines inherited from its former parent, covering cholesterol, blood pressure, respiratory and skin conditions, alongside a group of biosimilar antibodies used in immunology and oncology. It was spun out as an independent company, is based in Jersey City and sells through wholesalers, retailers and hospitals across many countries. Closelook has not set a peer group for this name; the comparison the market often draws is with Viatris, another company built from a big pharma's off-patent and legacy brands.

Where does Organon & Co sit in the AI build-out?

Organon carries no seat in the AI build-out stack; it sits in the diary's healthcare universe as a diversified drug maker, not as a constraint on or a customer of any layer we track for the build-out. Organon holds a seat in the Russell 1000 but carries no Closelook score yet, and the diary has not logged any quotes or editions on it so far.

Does Organon & Co pay a dividend?

Organon & Co has paid 0.0799 USD per share over the last twelve months, paid quarterly, a trailing yield of 0.58% on the 2026-09-17 close; the last distribution recorded in the price series was 0.0200 USD on 2026-08-14. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for OGN, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.